{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T02:28:55Z","timestamp":1786328935906,"version":"build-2736575974"},"reference-count":15,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2026,8]]},"abstract":"Abstract<\/jats:title>\n \n Background and Objectives<\/jats:title>\n Detecting Rh variants in transfusion recipients is essential to prevent alloimmunization. This study compared the serological reactivity of various monoclonal antibodies using two techniques (gel column agglutination and microplate technology at room temperature) in relation to genetically confirmed Rh variants.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods<\/jats:title>\n \n Over an 18\u2010month period, all EDTA blood samples referred to the molecular laboratory were analysed.\n RHD<\/jats:italic>\n and\n RHCE<\/jats:italic>\n genotyping was performed, and samples carrying at least one variant allele underwent serological testing. Statistical analysis was performed using the McNemar test (\n p<\/jats:italic>\n \u2009<\u20090.05).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 610 samples, 118 (19%) carried at least one Rh variant. The most frequent alleles were\n RHCE*CeRN<\/jats:italic>\n (\n n<\/jats:italic>\n \u2009=\u200939) and\n RHD*weak D type 1<\/jats:italic>\n (\n n<\/jats:italic>\n \u2009=\u200914). Weak RhD (types 1 and 3) and partial RhD from\n RHD*DAR<\/jats:italic>\n were serologically weakened (<4+) with both methods. Homozygosity for\n RHCE*CeRN<\/jats:italic>\n was suggested by serological weakening of RH5 with both methods, whereas heterozygosity was indicated by serological weakening of RH2 with microplate only. Other variants with a few samples (RH1 of\n RHD*weak D type 2 and 5<\/jats:italic>\n , RH2 of\n RHD*RHD\u2010CE (4\u20137)\u2010D<\/jats:italic>\n , RH3 of\n RHCE*cEIV<\/jats:italic>\n , RH4 of\n RHCE*ceJAL<\/jats:italic>\n and RH5 of\n RHCE*ceMO.01<\/jats:italic>\n and\n RHCE*ceAR<\/jats:italic>\n ) showed weak serological intensities but lacked statistical confirmation. Finally, 39% of Rh variants were not detected as serologically weakened by both serological methods.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Phenotyping remains the first\u2010line screening tool. Weak serological intensities help guide molecular investigations. However, detection of Rh variants using serology alone is highly variable. Combining different clones and techniques improves sensitivity.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/vox.70285","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:00:56Z","timestamp":1778248856000},"page":"1220-1227","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of serological reactivity in genetically confirmed\n Rh<\/scp>\n variants within a recipient population"],"prefix":"10.1111","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3267-6606","authenticated-orcid":false,"given":"Ma\u00eflis","family":"Lauwers","sequence":"first","affiliation":[{"name":"Laboratory of Immunohematology\/Blood Bank Department C.H.U. Brugmann Brussels Belgium"},{"name":"Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Akiki","sequence":"additional","affiliation":[{"name":"Laboratory of Immunohematology\/Blood Bank Department C.H.U. Brugmann Brussels Belgium"},{"name":"Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Bensaid","sequence":"additional","affiliation":[{"name":"Laboratory of Immunohematology\/Blood Bank Department C.H.U. Brugmann Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Bakrim","sequence":"additional","affiliation":[{"name":"Molecular Engineering, Biotechnology and Innovation Team, Polydisciplinary Faculty of Taroudant Ibn Zohr University Agadir Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Monfort","sequence":"additional","affiliation":[{"name":"Laboratory of Immunohematology\/Blood Bank Department C.H.C. Montl\u00e9gia Li\u00e8ge Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanane","family":"El Kenz","sequence":"additional","affiliation":[{"name":"Laboratory of Immunohematology\/Blood Bank Department C.H.U. Brugmann Brussels Belgium"},{"name":"Universit\u00e9 Libre de Bruxelles Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2019-217"},{"key":"e_1_2_9_3_1","unstructured":"ISBT.Red cell immunogenetics and blood group terminology | ISBT working party. Available from:https:\/\/www.isbtweb.org\/isbt-working-parties\/rcibgt-old.html. Last accessed 12 Nov 2025."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17132"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17740"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02382.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490623"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12309"},{"key":"e_1_2_9_9_1","volume-title":"Technical manual","author":"Cohn CS","year":"2023"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13792"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40030321.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2478\/immunohematology-2024-022"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes13061058"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.21037\/aob-20-84"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02970.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16355"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70285","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.70285","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:51:18Z","timestamp":1786326678000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/vox.70285"],"URL":"https:\/\/doi.org\/10.1111\/vox.70285","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}